Surgical Treatment of Aortic Stenosis With a Next Generation, Rapid Deployment Surgical Aortic Valve
Surgical Treatment of Aortic Stenosis With a Next Generation, Rapid Deployment Surgical Aortic Valve
The purpose of the clinical study is to prove that the heart valve device is safe, effective,
 and performs as intended.
This is a prospective, non-randomized, multi-center trial. Up to 950 subjects will be
 enrolled at up to 35 centers in the US. After replacement of their aortic heart valve with
 the EDWARDS INTUITY valve system, each patient will have routine follow-up tests at the
 following intervals: discharge, 3 months, 1 year, and annually thereafter for a minimum of
 five years.
Inclusion Criteria:

 -  Inclusion Criteria - Subjects will be required to meet all inclusion criteria:

 1. Male or female, age 18 years or older

 2. Has aortic stenosis or stenosis-insufficiency of an aortic valve requiring a
 planned replace-ment as indicated in the preoperative evaluation

 3. Is scheduled to undergo planned aortic valve replacement with or without
 concomitant coronary bypass surgery

 4. Provide written informed consent

 5. Geographically stable and agrees to attend follow-up assessments until all
 subjects have completed 5 years of follow up

 Exclusion Criteria:

 - Exclusion Criteria - Subjects will not be eligible for trial participation if any of the
 following criteria are present:

 1. Pure aortic insufficiency

 2. Requires emergency surgery

 3. Previous aortic valve replacement

 4. Had prior mitral, tricuspid or pulmonic valve surgery, which included implant of a
 bioprosthetic valve, mechanical valve, or annuloplasty ring that will remain in situ

 5. Requires multiple valve replacement/repair

 6. Requires a surgical procedure outside of the cardiac area (e.g., vascular
 endarterectomy, vascular bypass, tumor removal)

 7. Aneurysm of the aortic root and/or ascending aorta requiring surgical intervention

 8. Active endocarditis/myocarditis or endocarditis/ myocarditis within 3 months prior to
 the scheduled AVR surgery

 9. Myocardial infarction (MI) within thirty (30) days prior to valve replacement surgery

 10. Renal insufficiency as determined by creatinine ≥ 2.5 mg/dL at screening or end-stage
 renal disease requiring chronic dialysis

 11. Hyperparathyroidism

 12. MRI or CT-scan confirmed cerebrovascular accident (CVA), or transient ischemic attack
 (TIA) within 6 months (180 days) of the procedure

 13. Presence of non-cardiac disease limiting life expectancy to less than 12 months

 14. Hypertrophic obstructive cardiomyopathy (HOCM)

 15. Left ventricular ejection fraction ≤ 25%

 16. Documented history of substance (drug or alcohol) abuse within the last 5 years

 17. Echocardiographic evidence of an intra-cardiac mass, thrombus, or vegetation

 18. Hemodynamic or respiratory instability requiring inotropic support, mechanical
 circulatory support, or mechanical ventilation within 30 days prior to the procedure

 19. Pregnancy, lactation, or planning to become pregnant;

 20. Currently incarcerated or unable to give voluntary informed consent

 21. Leucopenia (WBC < 3.5x 103/µL), or acute anemia (Hgb < 10.0 gm/dL or 6 mmol/L), or
 thrombocytopenia (platelet count < 50x 103/µL), or history of bleeding diathesis or
 coagulopathy

 22. History of myxomatous disease/connective tissue disorders (e.g., Marfan's Syndrome)

 23. Current or recent participation (within 6 weeks prior to surgery) in an
 investigational drug or device trial

 -  Intra-operative Exclusion Criteria

 24. Anatomic variances which contraindicate implant of the trial valve, such as:

 1. anomalous coronary arteries

 2. annular deformation or extensive calcification of the annulus or aortic root
 which cannot be removed

 3. significant calcium on the anterior mitral leaflet

 4. pronounced septal calcification

 5. position of coronary ostia relative to Model 8300ACD valve that would result in
 obstruction of blood flow

 25. Available devices are not suitably sized for the subject's annulus